With its latest obesity play appearing to pay off, Regeneron has turned its attention to radiopharmaceuticals. | With its latest obesity play appearing to pay off, Regeneron has turned its attention ...
Stockhead on MSN
Health Check: Telix strikes surprise $3 billion-plus headline deal to develop next-gen therapies
In a deal potentially worth more than $3 billion, radiopharmaceuticals developer Telix has struck a deal to develop next-gen ...
PM Eastern, Lantern Pharma will host an exclusive live demonstration of withZeta.ai at Nasdaq MarketSite in New York City - one of the world's most recognized venues for presenting innovation to the ...
Telix Pharmaceuticals Limited TLX shares are up during Monday’s premarket session following a significant collaboration ...
Telix’s ( ASX:TLX) March-quarter precision medicine sales grew 16% on December 2025 to USD 186 million. Total revenue was USD ...
Merck built a wall of patents to keep a cancer drug's price – and its profits – high. Hospitals often add to the cost for ...
How are you dealing with the rising cost of fossil fuels? ‘The transition away from fossil fuels is a prerequisite for global ...
Kymera Therapeutics secures $45M as Gilead licenses KT-200, advancing a novel CDK2 degrader with potential in breast cancer ...
FUS utilizes multiple beams of relatively low-frequency ultrasound (generally within 0.2–3 MHz, depending on the application ...
Discover the hidden baby powder risks. Paediatricians warn that dusting powders can cause breathing issues, skin irritation, ...
Telix Pharmaceuticals Ltd (ASX: TLX) share price in focus as FDA accepts NDA for Pixclara, a glioma imaging agent.
The ASX has slipped on Friday as markets try to make sense of a “ceasefire” that still has oil routes half shut.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results